CClinicalTrials.gg
WithdrawnNCT04405050Updated Jul 24, 2023

RCT to Compare Restrata and NPWT to Heal Complex DFUs

A Phase 4 interventional study of Restrata and Negative Pressure Wound Therapy (NPWT) in Diabetic Wound, sponsored by University of Texas Southwestern Medical Center. Withdrawn at 1 site in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2023-07-24.

Sponsored by University of Texas Southwestern Medical Center · Phase 4, Interventional, and Treatment

Why this study was withdrawn
Project Never Initiated - no human subjects were enrolled and no data regarding humans was collected or studied.
Phase
Phase 4
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Study summary

The purpose of this study is to compare the efficacy of Restrata compared to Negative Pressure Wound Therapy (NPWT) to heal complex diabetic foot wounds.

Read the detailed description

Screening

  1. Explain purpose and nature of the study and obtain signature on the informed consent document.
  2. Screen the subject against protocol inclusion and exclusion criteria, including all pertinent tests, including pregnancy test if needed.

Baseline (may be done as same day as screening procedures)

  1. Obtain general medical history and demographic information and social history
  2. Complete a physical examination, body weight, height, and vital signs, including measurement of resting heart rate, respiratory rate, and blood pressure while seated.
  3. Select target study ulcer
  4. Obtain complete history pertinent to DFU disease including duration of the target ulcer, previous and current treatment.
  5. Perform debridement and obtain tissue collection (3 tissue and 1 bone if applicable).
  6. Perform standardized photography and measurement of the study wound (eKare or available camera with ruler). Assess the post-debridement ulcer area (cm2), perimeter (cm), and greatest depth (cm) using the inSight device (eKare, Fairfax, VA).
  7. Perform hyperspectral imaging of dorsal and plantar aspects of the foot.
  8. Perform neuropathy assessment (monofilament, VPT)
  9. Skin perfusion pressure (Sensilase)
  10. Collect all relevant concomitant medication (antibiotics, steroids, and diabetes medications)
  11. Complete questionnaires
  12. Place Restrata and dress wound or apply NPWT therapy.
  13. Submit subject stipend

Therapy/Treatment Phase

Study Visit 1-11:

  1. Assess target ulcer (if wound has closed, document as such, skip to END OF STUDY VISIT (EOS).
  2. Document time on/off NPWT if applicable.
  3. If Restrata is removed, assess the ulcer area (cm2), perimeter (cm), and greatest depth (cm) using the inSight device - if the wound is deemed healed by the physician, skip to EOS visit.
  4. Perform hyperspectral imaging of the dorsal and plantar aspects of the foot if wound is active or healed.
  5. Debride wound if indicated. Re-measure wound if surgical debridement is performed prior to dressing the wound
  6. Collect all relevant concomitant medication.
  7. If wound is not healed, redress the wound with Restrata dressing (if removed for debridement) or NPWT.
  8. Disburse subject stipend
  9. Note: at week 3, if wound is not ready for surgical closure, remove Restrata and replace with new piece of Restrata (per randomization schedule)
  10. Assess for AE/SAEs and/or follow up on previous AE/SAEs.

Study Visit Closed

  1. When a study wound has closed, we will perform the EOS evaluation.
  2. If a wound has closed, the patient will enter the follow-up phase of the study.

Study Visit 12/EOS:

  1. If the study wound closes prior to the 12-week study mark, subjects will perform EOS visit at the time of wound closure.
  2. Assess target ulcer.
  3. If wound has not closed, assess the ulcer area (cm2), perimeter (cm), and greatest depth (cm) using the inSight device.
  4. Perform hyperspectral imaging of the dorsal and plantar aspects of the foot if wound is active or healed.
  5. If wound has not closed, redress the wound per physician-directed standard of care.
  6. Perform EOS visit documentation
  7. Complete questionnaires
  8. Follow up on AE/SAEs that have not yet been resolved.

Study Visit Follow-up

  1. If the wound heals during the treatment phase or if the wound is not healed after 12 weeks, data from their electronic medical record will be evaluated to identify healing, time to heal, adverse events related to the wound.
02

Conditions studied

  • Diabetic Wound

Browse trials for

03

In context

Wounds and Injuries

5,056 studies on the registry are indexed under Wounds and Injuries; 861 are open to participants now.

Browse Wounds and Injuries studies →

Lead sponsor

University of Texas Southwestern Medical Center is the lead sponsor of 990 studies on the registry; 201 are open to participants now.

Of its 135 completed or terminated interventional studies of FDA-regulated products, 100 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Diagnosis of a diabetes mellitus
  • Men/women ≥21 years old
  • Post-operative foot or ankle wounds sized \< 15cm
  • ABI ≥0.5 or toe pressures >30 mmHg
  • Wounds indicated for treatment with NPWT

Exclusion criteria

Exclusion Criteria:

  • Active Charcot arthropathy
  • Unable to use NPWT at home
  • Untreated bone or soft tissue infection
  • Is pregnant or plans to become pregnant
  • Is nursing or actively lactating
  • Developmental disability/significant psychological disorder that in the opinion of the investigator could impair the subject's ability to provide informed consent, participate in the study protocol or record study measures, including untreated schizophrenia, bipolar disorder and psychiatric hospitalization within the last 2 years.
  • Active alcohol or substance abuse in the opinion of the investigator that could impair the subject's ability to provide informed consent, participate in the study protocol or record study materials. Active alcohol (> 14 drinks per week over the last 3 months) or substance abuse (current use of cocaine, heroin, or methamphetamines or if drug or alcohol use will interfere with follow-up visits in foot clinic in the opinion of the investigator
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Active comparator
    Restrata

    Treated with Restrata

    Device: Restrata

  • Active comparator
    NPWT

    Treated with NPWT (Negative Pressure Wound Therapy)

    Device: Negative Pressure Wound Therapy (NPWT)

Interventions

  • DeviceRestrata

    Restrata® is a novel synthetic nanofabricated scaffold (Restrata Wound Matrix (RWM), Acera Surgical, St. Louis, Missouri) has been developed which is a sterile, single-use device intended for use in the local management of wounds. The RWM is a soft, white, conformable, non-friable, absorbable matrix that acts as a protective covering for wound defects, providing a moist environment for the body's natural healing process to occur (Figure 2). The RWM is made from synthetic biocompatible materials and was designed to include a fibrous structure with high porosity, similar to native ECM. As a viable wrap for surgical procedures, Restrata conforms to injured tissue, can be sutured, and is arthroscopic and robotic procedure friendly.

  • DeviceNegative Pressure Wound Therapy (NPWT)

    Negative Pressure Wound Therapy (NPWT) has dramatically changed the care of complex foot wounds. Compared to standard wound care, patients with diabetic foot wounds that are treated with NPWT are 5.9 times more likely to heal and 4.4 times less likely to require amputation. NPWT involves the delivery of sub-atmospheric pressure through a vacuum pump connected to a specialized dressing to maintain a closed environment. NPWT increases perfusion to the wound, accelerates granulation tissue formation, reduces edema, and reduces bio-burden

06

What researchers measure

Primary outcomes

  1. Wound Closure

    The primary objective of this trial is to evaluate the incidence of wound closure. Closure is defined as complete epithelialization with no drainage.

    Time frame: 12 weeks

Secondary outcomes

  1. Time to wound healing

    Days to complete closure. Closure is defined as complete epithelialization with no drainage.

    Time frame: 12 weeks

  2. Differences in wound healing trajectories

    Defined as the change in wound area per week. Measured by wound measuring camera and PI observation/physical exam. Reported as mm\^2 per day.

    Time frame: 12 weeks

07

Study locations

1 site
  • UT Southwestern Medical Center at Dallas
    Dallas, Texas 75390, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04405050
Lead sponsor
University of Texas Southwestern Medical Center
Collaborators
Acera Surgical, Inc.
Responsible party
Larry Lavery (Professor and Director of Research, University of Texas Southwestern Medical Center) — Principal investigator
First posted
May 28, 2020
Start date
Jun 2021 (estimated)
Primary completion
Jul 2022 (estimated)
Completion
Jul 2023 (estimated)
Last update
Jul 24, 2023

Study contacts

Lawrence Lavery, DPM MPH
principal investigator · UT Southwestern Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion